Observational studyEndocrine2026
Long-Term experience with growth hormone therapy in pediatric growth disorders: an analysis of the LG growth study data.
Observational study in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01604395 (An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. / Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGrowth hormone (GH) therapy has been widely applied to improve height outcomes in pediatric patients experiencing growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), and small-for-gestational-age (SGA). This study aimed to evaluate long-term growth outcomes of recombinant human GH therapy across various indications in Korean pediatric patients.
methodsWe conducted a retrospective analysis utilizing 10-year longitudinal clinical data from the LG Growth Study (LGS), a multicenter, observational registry in Korea. Annual changes in height standard deviation scores (SDS) and growth velocity were primary outcomes, with subgroup analyses by age at initiation and diagnosis performed to identify determinants of treatment response.
resultsAs of December 2022, a total of 3,103 patients were included in the analysis. The mean age of the subjects was 7.43 ± 2.94 years. Among the patients, GHD comprised 69.1%, SGA 18.4%, ISS 9.8%, and TS 6.2%. After ten years of GH treatment, substantial improvements in height standard deviation scores (SDS) were observed in all patient groups. The most significant growth increase occurred during the first year and gradually diminished in subsequent years. In the GHD group, younger age at treatment initiation was associated with greater improvements in height SDS compared to older patients. Within the TS group, patients with mosaic karyotypes exhibited better responses than those with monosomy or structural chromosome abnormalities.
conclusionThis extensive real-world study demonstrates that GH therapy significantly improves linear growth outcomes in Korean patients across various growth disorders.
trial registrationClinicalTrials.gov Identifier NCT01604395.
Indexed as
Identifiers
41493505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.